Jam

Balmain Beauty enters the luxury fragrance market with “Destin de Balmain.” This debut scent embodies the brand’s heritage of sophistication and innovation, crafted with rare ingredients. Positioned as a prestige offering, it targets consumers who value exclusivity and refined aesthetics. The launch signifies a strategic expansion, aiming to diversify revenue and deepen brand storytelling through an accessible yet luxurious olfactory experience.

The FDA has accepted Genentech’s New Drug Application for giredestrant, an oral SERD, for ER+/HER2- advanced breast cancer with ESR1 mutations. This investigational drug targets a key resistance mechanism, potentially offering a less toxic alternative to chemotherapy for approximately 40% of patients with this mutation. Data from the Phase III EMERALD trial will guide the FDA’s review, which could lead to a significant advancement in precision oncology.

Agenus presented new biomarker data at ASCO, showing botensilimab (BOT) plus balstilimab (BAL) can stratify survival in MSS mCRC and other “cold” tumors. This immunotherapy combination shows promise in overcoming resistance by potentially activating the immune response in tumors that typically don’t respond to current checkpoint inhibitors. The data suggests successful identification of biomarkers that predict patient response, paving the way for personalized treatment strategies beyond colorectal cancer.

Republic Power Group Limited has completed a 1-for-20 reverse stock split to boost its market position. This move consolidates shares, aiming to increase the per-share price, attract institutional investors, and meet listing requirements. The company expects this strategic action to enhance financial stability, improve investor perception, and facilitate future growth and technological investment in the energy sector. Fractional shares will be settled in cash.

Synaptics Incorporated will present at the Raymond James Technology Investor Conference on February 26, 2026, and the Susquehanna Financial Group Annual Technology Conference on March 3, 2026. Management will discuss strategic vision, product roadmaps, and financial performance, focusing on edge AI, connectivity, and IoT. These events offer investors insights into Synaptics’ innovation in human-machine interface solutions across various markets and its positioning in the evolving semiconductor industry.

Visa Inc. is expanding its Latin American footprint by acquiring Argentine payment processors Prisma Medios de Pago and Newpay. This strategic move aims to bolster Visa’s market position, integrating Prisma’s established infrastructure with Newpay’s digital innovation. The acquisition is expected to enhance payment processing capabilities, drive digital transformation, and solidify Visa’s leadership in Argentina’s growing digital payments sector.